Trials / Completed
CompletedNCT05414461
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
Efficacy of PD-1-inhibitor-based Combination Therapy in Patients With Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combinations | PD-1 inhibitor-based combinaiton treatment |
Timeline
- Start date
- 2019-03-10
- Primary completion
- 2021-10-17
- Completion
- 2022-04-30
- First posted
- 2022-06-10
- Last updated
- 2022-06-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05414461. Inclusion in this directory is not an endorsement.